Stock listing

OTC:VCNX Vaccinex, Inc. Stock

Follow Vaccinex, Inc. into a list and get an email when it puts out news.

Share price · OTC:VCNX

$1.01 USD -0.04 (-4.2%)

Close on Oct 15, 2026

Vaccinex, Inc. logo
Ticker
OTC:VCNX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study

Oct 7, 2026

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

Jul 8, 2026

Vaccinex Reports 2025 Annual Financial Results

Apr 29, 2026

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

Dec 23, 2025

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Apr 21, 2025

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Mar 7, 2025

All Vaccinex, Inc. news

Decks

Vaccinex, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 7 in all · newest Oct 7, 2026 · oldest 2025
Decks
4 decks · latest Sep 13, 2022

Log in to ask 6ix AI your own questions about Vaccinex, Inc.